Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2

Status

Completed 5Withdrawn 1Unknown 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5Plasma cell 2Other solid neoplasm 2Other hematologic neoplasm 2Sarcoma 1Myeloid 1Classical hematology 1

Conditions

Lymphoma, T-Cell, Peripheral 4Lymphoma 2Hematologic Neoplasms 2Recurrence 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Leukemia 1Bone Marrow Neoplasms 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Rituximab 702Cyclophosphamide 645Vincristine 353Doxorubicin 309Etoposide 305Cytarabine 271Filgrastim 250Prednisone 249Methotrexate 241fludarabine phosphate 231Dexamethasone 209fludarabine 184Peripheral Blood Stem Cell Transplantation 166Radiotherapy 161Granulocyte Colony-Stimulating Factor 145Lenalidomide 144Bendamustine Hydrochloride 142Bortezomib 127Melphalan 126ibrutinib 111Busulfan 111Mycophenolic Acid 108Whole-Body Irradiation 107Tacrolimus 96Cyclosporine 87Gemcitabine 82Ifosfamide 80Calcium Dobesilate 80Alemtuzumab 80Leucovorin 78

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × darinaparsin × Lymphoid × Clear all
NCT02653976 2024-01-26

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Solasia Pharma K.K.

Phase 2 Completed
67 enrolled 13 charts
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01435863 2015-08-13

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

Solasia Pharma K.K.

Phase 1 Completed
17 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT01689220 2014-09-04

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

Solasia Pharma K.K.

Phase 1 Completed
6 enrolled
Lymphoid

Lymphoma, T-Cell, Peripheral

NCT00421213 2012-07-19

Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers

Alaunos Therapeutics

Phase 2 Completed
50 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Bone Marrow Neoplasms, Hematologic Neoplasms

NCT00592046 2012-07-19

A Phase I Trial of ZIO-101 in Hematologic Cancers

Alaunos Therapeutics

Phase 1 Completed
12 enrolled
Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Refractory, with Excess of Blasts, Leukemia, Lymphoma, Multiple Myeloma, Myeloproliferative Disorders, Recurrence, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡